Stockscreener 앱 받기
26.05
1.56%
0.40
시간 외 거래:
25.49
-0.56
-2.15%
전일 마감가:
$25.65
열려 있는:
$25.54
하루 거래량:
1.34M
Relative Volume:
0.50
시가총액:
$1.62B
수익:
$14.34M
순이익/손실:
$-199.00M
주가수익비율:
-6.6454
EPS:
-3.92
순현금흐름:
$-183.51M
1주 성능:
+5.47%
1개월 성능:
+2.88%
6개월 성능:
+96.16%
1년 성능:
+78.06%
1일 변동 폭
$25.01
$26.50
1주일 범위
$24.36
$28.48
52주 변동 폭
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
명칭
Uniqure N V
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
26.05 | 1.60B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2025-11-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure N V 주식(QURE)의 최신 뉴스
How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors - simplywall.st
Discipline and Rules-Based Execution in QURE Response - Stock Traders Daily
uniQure reports promising data from Fabry disease gene therapy trial By Investing.com - Investing.com Nigeria
UniQure's AMT-191 Sustains Key Enzyme Activity In Fabry Disease In Phase I/IIa Trial; Stock Up - Nasdaq
Uniqure stock rises after AMT-191 gene therapy shows promising Fabry results - Investing.com
uniQure (QURE) Shares Promising Data on Gene Therapy for Fabry D - GuruFocus
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - The Manila Times
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa - GlobeNewswire
uniQure (NASDAQ:QURE) Stock Price Up 8.6%What's Next? - MarketBeat
Here’s Why uniQure (QURE) Declined in Q4 - Yahoo Finance
Aug Opening: Why is uniQure NV stock going downWeekly Risk Summary & Fast Gain Stock Trading Tips - baoquankhu1.vn
uniQure (QURE) Is Down 9.4% After FDA Deems AMT-130 Data Insufficient for BLA Filing - Sahm
Stock Recap: Is uniQure NV stock risky to hold nowQuarterly Earnings Report & Expert Approved Trade Ideas - baoquankhu1.vn
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
Update Recap: Will uniQure NV benefit from geopolitical trendsJuly 2025 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ - marketscreener.com
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Aug Swings: Can uniQure NV continue delivering strong returnsInflation Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Privium Fund Management B.V. Sells 61,486 Shares of uniQure N.V. $QURE - MarketBeat
UniQure N.V. (QURE) Stock Analysis: A Biotech Player With 127.68% Potential Upside - DirectorsTalk Interviews
QURE Investigation Alert: Kessler Topaz Meltzer & Check, - GlobeNewswire
Geopolitics Watch: Can uniQure NV continue delivering strong returnsQuarterly Portfolio Review & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
uniQure (NASDAQ:QURE) Stock Rating Upgraded by Barclays - MarketBeat
Barclays Downgrades UniQure NV(QURE.US) to Hold Rating, Raises Target Price to $31 - 富途牛牛
Barclays Initiates Coverage of uniQure N.V. (QURE) with Equal-Weight Recommendation - Nasdaq
What Analysts Are Saying About uniQure Stock - Benzinga
Barclays Initiates Coverage on uniQure (QURE) with Equal-Weight Rating | QURE Stock News - GuruFocus
Barclays Initiates Coverage on uniQure N.V With Equal Weight Rating, $31 Price Target - marketscreener.com
Behavioral Patterns of QURE and Institutional Flows - Stock Traders Daily
Does uniQure N.V. have strong fundamentalsPortfolio Gains Summary & Safe Capital Growth Tips - mfd.ru
Trend Review: Is uniQure NV stock forming a triangle pattern2025 Year in Review & Safe Capital Growth Plans - baoquankhu1.vn
Genmab pauses enrollment in early ADC trial acquired from ProfoundBio - European Biotechnology Magazine
Retail Trends: Why is uniQure NV stock going downJuly 2025 Analyst Calls & Fast Gain Swing Alerts - baoquankhu1.vn
Huntington’s Advocates Press FDA to Approve UniQure’s Treatment - Bloomberg.com
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Shares Gap UpStill a Buy? - MarketBeat
uniQure N.V. $QURE Shares Sold by SG Americas Securities LLC - MarketBeat
Huntington's Disease Market Poised for Transformation Through - openPR.com
UNIQURE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - 富途资讯
QURE INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving uniQURE N.V. - ACCESS Newswire
Here’s Why uniQure (QURE) Fell in Q3 - Insider Monkey
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Prime Publishers, Inc.
Short Interest in uniQure N.V. (NASDAQ:QURE) Rises By 33.8% - MarketBeat
(QURE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
QURE Investigation Reminder: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
uniQure (NASDAQ:QURE) Shares Up 5%Here's What Happened - MarketBeat
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - MSN
Uniqure N V (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
7.16%
자본화:
|
볼륨(24시간):